Court Gives Biopharma Patent Owners (A Little) Help In Inter Partes Review
Executive Summary
In 9-4 en banc opinion, Federal Circuit finds PTAB decision that an inter partes review petition is not time-barred can be appealed; says Supreme Court left opening in Cuozzo ruling.
You may also be interested in...
IPR Battles Could Become Easier For BioPharma Patent Owners
En banc Federal Circuit says patent owners do not have to prove patentability of amended claims in inter partes review proceedings; judges issue five opinions in fractured decision.
Supreme Court Upholds IPR Standard Making Patent Invalidation Easier; Will Congress Reverse?
High court says inconsistent decisions by Patent Trial and Appeal Board and district court are okay; House and Senate bills would eliminate the broad standard but opposition by tech community could doom passage.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.